Cargando…
Triptolide inhibits epithelial-mesenchymal transition and induces apoptosis in gefitinib-resistant lung cancer cells
The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib, is used widely to treat non-small cell lung cancer (NSCLC) with EGFR-activating mutations. Unfortunately, the acquired drug resistance promoted by epithelial-mesenchymal transition (EMT) markedly limits the clinica...
Autores principales: | Li, Fangqiong, Cui, Huaizhong, Jin, Xin, Gong, Xiaoting, Wang, Wei, Wang, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107945/ https://www.ncbi.nlm.nih.gov/pubmed/32323848 http://dx.doi.org/10.3892/or.2020.7542 |
Ejemplares similares
-
Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial–mesenchymal transition
por: Deng, Qiu-di, et al.
Publicado: (2021) -
Inhibition of GPR30 sensitized gefitinib to NSCLC cells via regulation of epithelial-mesenchymal transition
por: Yang, Xiaomin, et al.
Publicado: (2023) -
Triptolide reverses epithelial-mesenchymal transition in glioma cells via inducing autophagy
por: Lai, Minfang, et al.
Publicado: (2021) -
Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013) -
Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
por: Hu, Yong, et al.
Publicado: (2017)